Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Health Canada/RYALTRIS

Authorized

STANDARD

RYALTRIS

Glenmark Specialty SA🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 9ed94d2bc2651de6
Company: Glenmark Specialty SA
Type: Standard

Approval Details

Approval Id: 9ed94d2bc2651de6
Drug Approval Canada Name: RYALTRIS
Product Name: RYALTRIS
Status: Marketed
Status Date: 2023-03-17
Original Market Date: 2023-03-17
Din: 02531186
Drug Class: Human
Dosage Form: Spray, Metered Dose
Route Of Administration: Nasal
Schedule: Prescription
Ahfs: 52:08.08
Atc Original: R01AD59 MOMETASONE, COMBINATIONS
Atc Name: r 01 ad 59
Aig Number: 0264081001
Company Name: Glenmark Specialty SA
Company Address: Place Du Port 2, Neuchâtel, --, Switzerland, 2000
Company Detail Path: /organization/glenmark-specialty-sa

Company Information

Pharmaceutical Company Name: Glenmark Specialty SA
Country Name: Switzerland
Province Name: Neuchâtel
City Name: neuchâtel,neuchâtel,country_ch
Address: place du Port 2

Active Ingredients

OLOPATADINE HYDROCHLORIDE

665 MCG / ACT

MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE)

25 MCG / ACT

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

9ed94d2bc2651de6

Type

Standard

Back to Health Canada Approvals

RYALTRIS - Health Canada Drug Approval Details